Leerink Partners previews the drugs likely to be subject to the Inflation Reduction Act’s next price negotiations as the ...

Immunic, Inc. ("Immunic" or the "Company") , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research ...

Leerink downgraded Rocket Pharmaceuticals (RCKT) to Market Perform from Outperform with a price target of $8, down from $37, after the company said a Danon disease patient participating in the Phase 2 ...

Rocket Pharmaceuticals acknowledged the death of a patient in a pivotal trial assessing its Danon disease gene therapy candidate RP-A501, a study that the FDA has placed on clinical hold.

Rocket Pharmaceuticals (RCKT) plunged nearly 63% on Tuesday, hitting an all-time low after the U.S. FDA placed a clinical ...

Rocket Pharmaceuticals faces trial delays, multiple downgrades, and reduced success expectations following RP-A501 safety ...